Pfizer stepped out strong in its first-quarter earnings report after its COVID vaccine and oral antiviral treatment, Paxloid combined to boost its revenue. The pharmaceutical giant’s first-quarter revenue grew 77 percent to more than $25 billion compared to the same period in 2021, according to an official financial statement released on Tuesday. The revenue growth […] read more Strong sales on COVID vaccine, oral treatment earns Pfizer $15bn in Q1